Abstract：
Aloe-emodin (AE) is an anthraquinone derivative and a biologically active component sourced from various plants, including Rheum palmatum L. and Aloe vera. Known chemically as 1,8-dihydroxy-3-hydroxymethyl-anthraquinone, AE has a rich history in traditional medicine and is esteemed for its accessibility, safety, affordability, and effectiveness. AE boasts multiple biochemical and pharmacological properties, such as strong antibacterial, antioxidant, and antitumor effects. Despite its array of benefits, AE\'s identity as an anthraquinone derivative raises concerns about its potential for liver and kidney toxicity. Nevertheless, AE is considered a promising drug candidate due to its significant bioactivities and cost efficiency. Recent research has highlighted that nanoformulated AE may enhance drug delivery, biocompatibility, and pharmacological benefits, offering a novel approach to drug design. This review delves into AE\'s pharmacological impacts, mechanisms, pharmacokinetics, and safety profile, incorporating insights from studies on its nanoformulations. The goal is to outline the burgeoning research in this area and to support the ongoing development and utilization of AE-based therapies.
摘要：
芦荟大黄素（AE）是蒽醌衍生物和生物活性成分，来自各种植物，包括掌叶大黄和芦荟。化学上称为1,8-二羟基-3-羟甲基-蒽醌，AE在传统医学方面有着悠久的历史，并因其可及性而受到尊敬，安全,负担能力，和有效性。AE具有多种生化和药理特性，如强抗菌，抗氧化剂，和抗肿瘤作用。尽管它有很多好处，AE作为蒽醌衍生物的身份引起了人们对其潜在的肝和肾毒性的担忧。然而，AE由于其显著的生物活性和成本效率而被认为是有前途的候选药物。最近的研究强调，纳米配方的AE可能会增强药物递送，生物相容性，和药理益处，提供了一种新颖的药物设计方法。这篇综述深入研究了AE的药理影响，机制,药代动力学，和安全概况，结合对其纳米配方研究的见解。目标是概述该领域的新兴研究，并支持基于AE的疗法的持续开发和利用。
